Evidence map›Paper›PMID 40358665›Full record

Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Impact of renal function on non-hematologic toxicities in mCRC patients treated with TAS-102: a post-hoc analysis of the JASCC-CINV2001 study.

Hironori Fujii, Masami Tsuchiya, Daichi Watanabe, Miki Chin, Daisuke Hirate, Katsuyuki Takahashi, Makiko Go, Toshihiro Kudo, Kazuhiro Shimomura, Yosuke Ando and 14 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Hironori FujiiDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Masami TsuchiyaDepartment of Pharmacy, Miyagi Cancer Center, Miyagi, Japan.
Daichi WatanabeDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Miki ChinDepartment of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Daisuke HirateDepartment of Pharmacy, Teine Keijinkai Hospital, Hokkaido, Japan.
Katsuyuki TakahashiDepartment of Pharmacy, Osaka City University Hospital, Osaka, Japan.
Makiko GoDepartment of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Toshihiro KudoDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Kazuhiro ShimomuraDepartment of Pharmacy, Aichi Cancer Center Hospital, Aichi, Japan.
Yosuke AndoDepartment of Pharmacotherapeutics and Informatics, Fujita Health University, Aichi, Japan.
Shinya TaniDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takao TakahashiDepartment of Gastroenterological Surgery, Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Katsuhisa HayashiDepartment of Pharmacy, Miyagi Cancer Center, Miyagi, Japan.
Hironobu HashimotoDepartment of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Naomi MatsunamiDepartment of Pharmacy, Teine Keijinkai Hospital, Hokkaido, Japan.
Masaya TakahashiDepartment of Pharmacy, Osaka City University Hospital, Osaka, Japan.
Akiko HasegawaDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Takashi UchidaDepartment of Pharmacy, Miyagi Cancer Center, Miyagi, Japan.
Akiko KuboDepartment of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Nobuhisa MatsuhashiDepartment of Gastroenterological Surgery, Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Akio SuzukiDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Junichi NishimuraDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Naoki InuiDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan. iihara.hirotoshi.p7@f.gifu-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough the efficacy of trifluridine/tipiracil hydrochloride (TAS-102) in treating metastatic colorectal cancer (mCRC) is well established, its non-hematologic toxicities in relation to renal function remain unclear. This study aimed to assess the impact of creatinine clearance (Ccr) on non-hematologic toxicities, including nausea and vomiting, in patients with mCRC treated with TAS-102.

methodsThis study was conducted as a post-hoc analysis of the JASCC-CINV2001 study, a multicenter observational study of mCRC patients. Using a Cox proportional hazards model, we assessed the relationship between Ccr and nausea or vomiting, and used a generalized estimating equations (GEE) logistic regression model to analyze the association between Ccr and additional toxicities, including fatigue, constipation, diarrhea, insomnia, and dysgeusia. Toxicities were evaluated at weekly intervals over four weeks.

resultsAmong 100 patients, median Ccr was 80.5 ml/min. The primary analysis showed no significant association between Ccr and nausea or vomiting. However, the secondary analysis revealed a significant link between lower Ccr and the incidence of diarrhea (P = 0.02).

conclusionThese results suggest that although TAS-102-induced nausea and vomiting are not strongly influenced by renal function, decreased renal function increases the risk of diarrhea. Enhanced antiemetic measures may not be necessary for TAS-102 patients with impaired renal function, but monitoring for diarrhea is recommended.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsTrifluridineUracilAdultAgedAged, 80 and overCreatinineDiarrheaDrug CombinationsFemaleHumansLogistic ModelsMaleMiddle AgedNauseaAntineoplastic AgentsCreatinineDrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilChemotherapy-induced nausea and vomitingNon-hematologic toxicitiesRenal functionTrifluridine/tipiracilUnresectable colorectal cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.